Previous observational studies and clinical trials have shown that cholinesterase inhibitors (with or without memantine) provide benefit for patients with mild-to-moderate Alzheimer’s disease. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.